JAK inhibitor helps in refractory RA
A trial of the JAK inhibitor baricitinib shows it can reduce RA symptoms even in patients who have had a poor response to previous treatment, according to a report in the NEJM.
The three-armed randomised controlled trial divided 527 patients equally between 4mg and 2mg daily doses of the drug and placebo. Patients were enrolled at 178 centres across 24 countries.
Fifty-five percent of patients in